Citigroup’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-6,300
Closed -$627K – 6907
2020
Q4
$627K Buy
6,300
+300
+5% +$27.4K ﹤0.01% 4004
2020
Q3
$572K Sell
6,000
-5,600
-48% -$613K ﹤0.01% 3741
2020
Q2
$1.3M Buy
11,600
+5,500
+90% +$559K ﹤0.01% 3272
2020
Q1
$444K Sell
6,100
-21,300
-78% -$1.94M ﹤0.01% 3976
2019
Q4
$2.86M Buy
27,400
+8,400
+44% +$900K ﹤0.01% 2600
2019
Q3
$1.89M Buy
19,000
+8,900
+88% +$896K ﹤0.01% 2932
2019
Q2
$1.15M Sell
10,100
-9,300
-48% -$1.1M ﹤0.01% 3452
2019
Q1
$2.44M Buy
19,400
+14,500
+296% +$1.76M ﹤0.01% 2466
2018
Q4
$665K Sell
4,900
-400
-8% -$68.4K ﹤0.01% 3827
2018
Q3
$1.46M Buy
5,300
+4,600
+657% +$1.11M ﹤0.01% 3076
2018
Q2
$145K Sell
700
-3,500
-83% -$626K ﹤0.01% 5372
2018
Q1
$694K Sell
4,200
-2,400
-36% -$380K ﹤0.01% 3635
2017
Q4
$904K Sell
6,600
-1,300
-16% -$181K ﹤0.01% 3432
2017
Q3
$1.08M Buy
7,900
+6,900
+690% +$876K ﹤0.01% 3286
2017
Q2
$121K Sell
1,000
-1,500
-60% -$168K ﹤0.01% 5198
2017
Q1
$265K Sell
2,500
-7,500
-75% -$791K ﹤0.01% 4427
2016
Q4
$1.02M Buy
10,000
+9,200
+1,150% +$931K ﹤0.01% 3675
2016
Q3
$82K Buy
+800
New +$94.2K ﹤0.01% 5333

Other funds holding LGND

Citigroup's LGND Position: Q3 2026 in Review

Citigroup increased its Ligand Pharmaceuticals (LGND) stake by 95% in Q3 2026, buying an estimated $18.7M and bringing the position to 129,988 shares worth $40.6M. The position accounts for 0.01% of the portfolio, ranked #855.

Citigroup first reported a position in LGND in Q2 2013 and has held it in 54 quarters since. 433 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Citigroup held 129,988 shares of Ligand Pharmaceuticals worth $40.6M as of Q3 2026.
  • Citigroup bought 63,349 Ligand Pharmaceuticals shares in Q3 2026, an estimated $18.7M.
  • Ligand Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q3 2026, its #855 holding.
  • Citigroup first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
  • 433 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.